Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15728476rdf:typepubmed:Citationlld:pubmed
pubmed-article:15728476lifeskim:mentionsumls-concept:C1155003lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C0037083lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C0031671lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C0033634lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C1413221lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C0031669lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C1823153lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C1710082lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C2611812lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C2349976lld:lifeskim
pubmed-article:15728476lifeskim:mentionsumls-concept:C1552644lld:lifeskim
pubmed-article:15728476pubmed:issue5lld:pubmed
pubmed-article:15728476pubmed:dateCreated2005-2-24lld:pubmed
pubmed-article:15728476pubmed:abstractTextThe CD38 cell surface receptor is a potent activator for splenic, B lymphocytes. The molecular mechanisms regulating this response, however, remain incompletely characterized. Activation of the nonreceptor tyrosine kinase, Btk, is essential for CD38 downstream signaling function. The major Btk-dependent substrate in B cells, phospholipase C-gamma2 (PLC-gamma2), functions to generate the key secondary messengers, inositol-1,4,5 trisphosphate and diacylglycerol. Surprisingly, CD38 ligation results in no detectable increase in phosphoinositide metabolism and only a minimal increase in cytosolic calcium. We hypothesized that Btk functioned independently of PLC-gamma2 in the CD38 signaling pathway. Accordingly, we demonstrate that CD38 cross-linking does not result in the functional phosphorylation of PLC-gamma2 nor an increase in inositol-1,4,5 trisphosphate production. Furthermore, splenic B cells exhibit a normal CD38-mediated, proliferative response in the presence of the phosphoinositide-PLC inhibitor, U73122. Conversely, protein kinase C (PKC) beta-deficient mice, or PKC inhibitors, indicated the requirement for diacylglycerol-dependent PKC isoforms in this pathway. Loss of PKC activity blocked CD38-dependent, B cell proliferation, NF-kappaB activation, and subsequent expression of cyclin-D2. These results suggested that an alternate diacylglycerol-producing phospholipase must participate in CD38 signaling. Consistent with this idea, CD38 increased the enzymatic activity of the phosphatidylcholine (PC)-metabolizing enzymes, PC-PLC and phospholipase D. The PC-PLC inhibitor, D609, completely blocked CD38-dependent B cell proliferation, IkappaB-alpha degradation, and cyclin-D2 expression. Analysis of Btk mutant B cells demonstrated a partial requirement for Btk in the activation of both enzymes. Taken together, these data demonstrate that CD38 initiates a novel signaling cascade leading to Btk-, PC-PLC-, and phospholipase D-dependent, PLC-gamma2-independent, B lymphocyte activation.lld:pubmed
pubmed-article:15728476pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:languageenglld:pubmed
pubmed-article:15728476pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:citationSubsetAIMlld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728476pubmed:statusMEDLINElld:pubmed
pubmed-article:15728476pubmed:monthMarlld:pubmed
pubmed-article:15728476pubmed:issn0022-1767lld:pubmed
pubmed-article:15728476pubmed:authorpubmed-author:Santos-Argume...lld:pubmed
pubmed-article:15728476pubmed:authorpubmed-author:RawlingsDavid...lld:pubmed
pubmed-article:15728476pubmed:authorpubmed-author:ZentellaAleja...lld:pubmed
pubmed-article:15728476pubmed:authorpubmed-author:HumphriesLisa...lld:pubmed
pubmed-article:15728476pubmed:authorpubmed-author:Moreno-García...lld:pubmed
pubmed-article:15728476pubmed:authorpubmed-author:López-Bojórqu...lld:pubmed
pubmed-article:15728476pubmed:issnTypePrintlld:pubmed
pubmed-article:15728476pubmed:day1lld:pubmed
pubmed-article:15728476pubmed:volume174lld:pubmed
pubmed-article:15728476pubmed:ownerNLMlld:pubmed
pubmed-article:15728476pubmed:authorsCompleteYlld:pubmed
pubmed-article:15728476pubmed:pagination2687-95lld:pubmed
pubmed-article:15728476pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:meshHeadingpubmed-meshheading:15728476...lld:pubmed
pubmed-article:15728476pubmed:year2005lld:pubmed
pubmed-article:15728476pubmed:articleTitleCD38 signaling regulates B lymphocyte activation via a phospholipase C (PLC)-gamma 2-independent, protein kinase C, phosphatidylcholine-PLC, and phospholipase D-dependent signaling cascade.lld:pubmed
pubmed-article:15728476pubmed:affiliationDepartments of Cell Biology, Centro de Investigación y Estudios Avanzados, Mexico D.F. Mexico.lld:pubmed
pubmed-article:15728476pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15728476pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15728476pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:12229entrezgene:pubmedpubmed-article:15728476lld:entrezgene
entrez-gene:18751entrezgene:pubmedpubmed-article:15728476lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15728476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15728476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15728476lld:pubmed